The unapproved but very online weight-loss drug

Online vendors are currently selling unapproved weight-loss drugs with few barriers to entry. Retatrutide, an investigational drug from Eli Lilly, is available through websites that bypass traditional supply chains. These sites often label the product as research use only to skirt federal oversight. The FDA has issued warning letters to 16 companies regarding the distribution of this substance but many continue to operate without significant interruption. Some vendors require simple account creation while others allow purchases directly through digital payment methods like bitcoin.

Experts note that warning letters alone do not stop these operations. Criminal investigations and direct seizures of inventory serve as the primary tools for curbing this black market. The growth of these online storefronts demonstrates the difficulty the FDA faces in policing goods that move outside standard pharmacies. These companies frequently use disclaimers to mask their true intent while providing consumers with the necessary equipment to reconstitute the drugs.

Meanwhile, in legal developments, a federal appeals court revived hundreds of lawsuits against Kenvue over Tylenol. The court overturned a previous decision that blocked expert testimony regarding the potential link between acetaminophen use during pregnancy and neurodevelopmental conditions. Plaintiffs argue this ruling validates their scientific evidence and allows the case to move toward a jury trial. Kenvue maintains that the science does not support these claims and intends to continue its defense in court.

Separately, the FDA plans to hold an advisory committee meeting for Sydnexis regarding their pediatric myopia treatment after an initial rejection. The agency also announced a public meeting on the therapeutic use of psychedelics for mental health. These shifts occur as the administration pushes for faster drug approvals and expanded access to treatments for serious mental illnesses.